rospedРоссийский педиатрический журнал имени М.Я. СтуденикинаM.Ya. Studenikin Russian Pediatric JournalФГАУ «НМИЦ здоровья детей» Минздрава России10.46563/1560-9561-2022-25-4-225-229cdxwfgrosped-213Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL INVESTIGATIONSУспешное применение ингибитора янус-киназ для лечения атопического дерматитаSuccessful use of a janus kinase inhibitor for the treatment of atopic dermatitishttps://orcid.org/0000-0002-1149-7927РевякинаВера АфанасьевнаRevyakinaVera A.

Доктор мед. наук, проф., ФГБУН «ФИЦ питания, биотехнологии и безопасности пищи», ФГАУ «НМИЦ здоровья детей».

e-mail: 5356797@mail.ru

5356797@mail.ruhttps://orcid.org/0000-0001-8549-9493МухортыхВалерий АлексеевичMukhortykhValera A.

Канд. мед. наук, мл. науч. сотр. ФГБУН «ФИЦ питания, биотехнологии и безопасности пищи».

e-mail: valera-89@yandex.ru

valera-89@yandex.ruhttps://orcid.org/0000-0001-7640-0754ЛарьковаИнна АнатольевнаLarkovaInna A.

Канд. мед. наук, ст. науч. сотр. ФГБУН «ФИЦ питания, биотехнологии и безопасности пищи».

e-mail: inna_larkova@mail.ru

MD, PhD, senior researcher, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow, 115446, Russian Federation; National Medical Research Center for Children’s Health, Moscow, 119991, Russian Federation.

e-mail: inna_larkova@mail.ru

inna_larkova@mail.ruhttps://orcid.org/0000-0002-3004-6646ГлуховаЕвгения АлександровнаGlukhovaEvgeniya A.

Врач-дерматолог ФГБУН «ФИЦ питания, биотехнологии и безопасности пищи».

e-mail: evgeniya.shmeleva1994@yandex.ru

evgeniya.shmeleva1994@yandex.ruКувшиноваЕлена ДмитриевнаKuvshinovaElena D.

Канд. мед. наук, ст. науч. сотр. ФГБУН «ФИЦ питания, биотехнологии и безопасности пищи», ФГАУ «НМИЦ здоровья детей».

e-mail: len.kuwshinowa@yandex.ru

len.kuwshinowa@yandex.ruhttps://orcid.org/0000-0001-7008-3815ТимофееваАнна МихайловнаTimofeevaAnna M.

Мл. науч. сотр. ФГБУН «ФИЦ питания, биотехнологии и безопасности пищи».

e-mail: annushec@mail.ru

annushec@mail.ruФГБУН «Федеральный исследовательский центр питания, биотехнологии и безопасности пищи»; ФГАУ «Национальный медицинский исследовательский центр здоровья детей» Минздрава РоссииThe Federal Research Center for Nutrition, Biotechnology and Food Safety; National Medical Research Center for Children’s HealthФГБУН «Федеральный исследовательский центр питания, биотехнологии и безопасности пищи»The Federal Research Center for Nutrition, Biotechnology and Food Safety202227092023254225229Copyright © Ревякина В.А., Мухортых В.А., Ларькова И.А., Глухова Е.А., Кувшинова Е.Д., Тимофеева А.М., 20232023Ревякина В.А., Мухортых В.А., Ларькова И.А., Глухова Е.А., Кувшинова Е.Д., Тимофеева А.М.Revyakina V.A., Mukhortykh V.A., Larkova I.A., Glukhova E.A., Kuvshinova E.D., Timofeeva A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rosped.ru/jour/article/view/213

В статье приводится клинический случай применения нового препарата ингибитора янус-киназ — упадацитиниба, оказывающего действие на внутриклеточную систему JAK/STAT, роль которой активно изучается в патогенезе атопического дерматита (АтД). JAK/STAT включает в себя янус-киназы JAK1, JAK2, JAK3, тирозинкиназу, белок-трансдуктор и активатор транскрипции (STAT). При взаимодействии цитокина с соответствующим рецептором янус-киназы фосфорилируют белки STAT и индуцируют транскрипцию генов, которые опосредуют действие ключевых цитокинов, вызывающих развитие воспалительной реакции при АтД. Упадацитиниб рекомендован больным АтД начиная с 12 лет, у которых лечение стандартными методами не позволило достичь необходимого благоприятного эффекта. Авторы установили, что применение удапацитиниба у пациентки 17 лет в дозе 15 мг/сут в таблетках обеспечивает высокую эффективность лечения в виде достижения клинической ремиссии АтД и полного купирования зуда.

Участие авторов

Участие авторов:Ревякина В.А., Ларькова И.А. — концепция и дизайн работы;Мухортых В.А., Глухова Е.А., Кувшинова Е.Д., Тимофеева А.М. — подготовка материала;Ревякина В.А., Ларькова И.А. — написание текста.Все соавторы — утверждение окончательного варианта статьи, ответственность за целостность всех частей статьи.

Финансирование

Финансирование. Исследование не имело финансовой поддержки. 

Конфликт интересов

Конфликт интересов. Авторы заявляют об отсутствии конфликта интересов.

Поступила 07

Поступила 07.06.2022Принята к печати 29.06.2022Опубликована 30.08.2022

The article presents a clinical report of the use of a new drug of the janus kinase inhibitor, upadacitinib, possessing of the effect on the intracellular JAK/STAT system, the role of which in the pathogenesis of atopic dermatitis (AD) is being actively studied. JAK/STAT includes janus kinases JAK1, JAK2, JAK3, tyrosine kinase, protein-transductor and transcription activator (STAT). When the cytokine interacts with the corresponding receptor, janus kinases phosphorylate STAT proteins inducing transcription of genes that mediate the action of key cytokines to trigger the development of an inflammatory response in the shock organ. Upadacitinib is recommended for uncontrolled AD patients older 12 years. The use of upadacitinib in a 17-year-old patient at a dose of 15 mg in tablets, daily, has shown high efficacy in achieving clinical remission of AD and complete relief of the skin itching.

Contribution

Contribution:Revyakina V.A., Larkova I.A. — concept and design of the work;Mukhortykh V.A., Glukhova E.A., Kuvshinova E.D., Timofeeva A.M. — preparation of the material;Revyakina V.A., Larkova I.A. — writing the text.All co-authors — approval of the final version of the article, responsibility for the integrity of all parts of the article.

Acknowledgment

Acknowledgment. The study had no sponsorship.

Conflict of interest

Conflict of interest. The authors declare no conflict of interest.

Received

Received: June 07, 2022Accepted: June 29, 2022Published: August 30, 2022

атопический дерматитдетиТh2-воспалениебиологическая терапияупадацитинибингибитор янус-киназыatopic dermatitischildrenTh2-inflammationbiological therapyupadacitinibjanus kinase inhibitorReferencesRoduit C., Frei R., Depner M., Karvonen A.M., Renz H., Braun-Fahrländer C., et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. JAMA Pediatr. 2017; 171(7): 655-62. https://doi.org/10.1001/jamapediatrics.2017.0556Roduit C., Frei R., Depner M., Karvonen A.M., Renz H., Braun-Fahrländer C., et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. JAMA Pediatr. 2017; 171(7): 655–62. https://doi.org/10.1001/jamapediatrics.2017.0556Хамаганова И.В., Новожилова О.Л., Воронцова И.В. Эпидемиология атопического дерматита. Клиническая дерматология и венерология. 2017; 16(4): 21-5. https://doi.org/10.17116/klinderma201716421-25Khamaganova I.V., Novozhilova O.L., Vorontsova I.V. Epidemiology of atopic dermatitis. Klinicheskaya dermatologiya i venerologiya. 2017; 16(4): 21–5. https://doi.org/10.17116/klinderma201716421-25 (in Russian)Смирнова Г.И. Актуальный атопический дерматит: достижения и перспективы. Российский педиатрический журнал. 2017; 20(2): 99-107. https://doi.org/10.18821/1560-9561-2017-20(2)-99-107Smirnova G.I. Current concepts of atopic dermatitis in children: problems and prospects. Rossiyskiy pediatricheskiy zhurnal. 2017; 20(2): 99–107. https://doi.org/10.18821/1560-9561-2017-20(2)-99-107 (in Russian)Yang Y.B., Gohari A., Lam J. Brief academic review and clinical practice guidelines for pediatric atopic dermatitis. Curr. Pediatr. Rev. 2021; 17(3): 229-37. https://doi.org/10.2174/1573396316999200820163434Yang Y.B., Gohari A., Lam J. Brief academic review and clinical practice guidelines for pediatric atopic dermatitis. Curr. Pediatr. Rev. 2021; 17(3): 229–37. https://doi.org/10.2174/1573396316999200820163434Mancuso J.B., Lee S.S., Paller A.S., Ohya Y., Eichenfield L.F. Management of severe atopic dermatitis in pediatric patients. J. Allergy Clin. Immunol. Pract. 2021; 9(4): 1462-71. https://doi.org/10.1016/j.jaip.2021.02.017Mancuso J.B., Lee S.S., Paller A.S., Ohya Y., Eichenfield L.F. Management of severe atopic dermatitis in pediatric patients. J. Allergy Clin. Immunol. Pract. 2021; 9(4): 1462–71. https://doi.org/10.1016/j.jaip.2021.02.017Ларькова И.А., Глухова Е.А., Ревякина В.А. Эффективность и безопасность иммунобиологической терапии атопического дерматита у детей. Российский педиатрический журнал. 2022; 25(1): 46-51. https://doi.org/10.46563/1560-9561-2022-25-1-46-51Lar’kova I.A., Glukhova E.A., Revyakina V.A. The efficacy and safety of immunobiological therapy of atopic dermatitis in children. Rossiyskiy pediatricheskiy zhurnal. 2022; 25(1): 46–51. https://doi.org/10.46563/1560-9561-2022-25-1-46-51 (in Russian)Saini S., Pansare M. New insights and treatments in atopic dermatitis. Immunol. Allergy Clin North Am. 2021; 41(4): 653-65. https://doi.org/10.1016/j.iac.2021.07.005Saini S., Pansare M. New insights and treatments in atopic dermatitis. Immunol. Allergy Clin North Am. 2021; 41(4): 653–65. https://doi.org/10.1016/j.iac.2021.07.005Janmohamed S.R., Ring J., Eichenfield L.F., Gutermuth J. Medical algorithm: Treatment of atopic dermatitis in early childhood (part II). Allergy. 2021; 76(1): 407-10. https://doi.org/10.1111/all.14512Janmohamed S.R., Ring J., Eichenfield L.F., Gutermuth J. Medical algorithm: Treatment of atopic dermatitis in early childhood (part II). Allergy. 2021; 76(1): 407–10. https://doi.org/10.1111/all.14512Klasa B., Cichocka-Jarosz E. Atopic dermatitis - current state of research on biological treatment. J. Mother Child. 2020; 24(1): 53-66. https://doi.org/10.34763/jmotherandchild.2020241.2003.0000010Klasa B., Cichocka-Jarosz E. Atopic dermatitis – current state of research on biological treatment. J. Mother Child. 2020; 24(1): 53–66. https://doi.org/10.34763/jmotherandchild.2020241.2003.0000010Ghamrawi R., Bell K.A., Balogh E.A., Strowd L.C., Feldman S.R. Current and emerging biologics for the treatment of pediatric atopic dermatitis. Expert. Opin. Biol. Ther. 2020; 20(12): 1435-45. https://doi.org/10.1080/14712598.2021.1840548Ghamrawi R., Bell K.A., Balogh E.A., Strowd L.C., Feldman S.R. Current and emerging biologics for the treatment of pediatric atopic dermatitis. Expert. Opin. Biol. Ther. 2020; 20(12): 1435–45. https://doi.org/10.1080/14712598.2021.1840548Ревякина В.А., Таганов А.В., Кувшинова Е.Д., Ларькова И.А., Мухортых В.А. Атопический дерматит, современная стратегия в терапии. Лечащий врач. 2019; (5): 32-7Revyakina V.A., Taganov A.V., Kuvshinova E.D., Lar’kova I.A., Mukhortykh V.A. Atopic dermatitis, a modern strategy in therapy. Lechashchiy vrach. 2019; (5): 32–7. (in Russian)Siegels D., Heratizadeh A., Abraham S., Binnmyr J., Brockow K., Irvine A.D., et al. Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis. Allergy. 2021; 76(4): 1053-76. https://doi.org/10.1111/all.14631Siegels D., Heratizadeh A., Abraham S., Binnmyr J., Brockow K., Irvine A.D., et al. Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis. Allergy. 2021; 76(4): 1053–76. https://doi.org/10.1111/all.14631Silverberg J.I., Thyssen J.P., Fahrbach K., Mickle K., Cappelleri J.C., Romero W., et al.Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J. Eur. Acad. Dermatol. Venerol. 2021; 35(9): 1797-10. https://doi.org/10.1111/jdv.17351Silverberg J.I., Thyssen J.P., Fahrbach K., Mickle K., Cappelleri J.C., Romero W., et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J. Eur. Acad. Dermatol. Venerol. 2021; 35(9): 1797–10. https://doi.org/10.1111/jdv.17351Newsom M., Bashyam A.M., Balogh E.A., Feldman S.R., Strowd L.C. New and emerging systemic treatments for atopic dermatitis. Drugs. 2020; 80(11): 1041-52. https://doi.org/10.1007/s40265-020-01335-7Newsom M., Bashyam A.M., Balogh E.A., Feldman S.R., Strowd L.C. New and emerging systemic treatments for atopic dermatitis. Drugs. 2020; 80(11): 1041–52. https://doi.org/10.1007/s40265-020-01335-7Le M., Berman-Rosa M., Ghazawi F.M., Bourcier M., Fiorillo L., Gooderham M., et al. Systematic review on the efficacy and safety of oral janus kinase inhibitors for the treatment of atopic dermatitis. Front. Med. (Lausanne). 2021; 8: 682547. https://doi.org/10.3389/fmed.2021.682547Le M., Berman-Rosa M., Ghazawi F.M., Bourcier M., Fiorillo L., Gooderham M., et al. Systematic review on the efficacy and safety of oral janus kinase inhibitors for the treatment of atopic dermatitis. Front. Med. (Lausanne). 2021; 8: 682547. https://doi.org/10.3389/fmed.2021.682547Li C., Sun X., Zhao K., Meng F., Li L., Mu Z., et al. Efficacy and safety of janus kinase inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis. Dermatology. 2022; 238(4): 725-35. https://doi.org/10.1159/000518541Li C., Sun X., Zhao K., Meng F., Li L., Mu Z., et al. Efficacy and safety of janus kinase inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis. Dermatology. 2022; 238(4): 725–35. https://doi.org/10.1159/000518541Bao L., Zhang H., Chan L.S. The involvement of the JAK-STAT signaling pathway in chronic in ammatory skin disease atopic dermatitis. JAKSTAT. 2013; 2(3) e24137. https://doi.org/10.4161/jkst.24137Bao L., Zhang H., Chan L.S. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013; 2(3) e24137. https://doi.org/10.4161/jkst.24137Новиков П.И., Шевцова Т.П., Щеголева Е.М., Моисеев С.В. Ингибиторы янус-киназ: фармакологические свойства и сравнительные клиническая эффективность и безопасность. Клиническая фармакология и терапия. 2021; 30(1): 51-60. https://doi.org/10.32756/0869-5490-2021-1-51-60Novikov P.I., Shevtsova T.P., Shchegoleva E.M., Moiseev S.V. Janus kinase inhibitors: pharmacological properties and comparative clinical efficacy and safety. Klinicheskaya farmakologiya i terapiya. 2021; 30(1): 51–60. https://doi.org/10.32756/0869-5490-2021-1-51-60 (in Russian)Blauvelt A., Teixeira H.D., Simpson E.L., Costanzo A., De Bruin-Weller M., Barbarot S., et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021; 157(9): 1047-55. https://doi.org/10.1001/jamadermatol.2021.3023Blauvelt A., Teixeira H.D., Simpson E.L., Costanzo A., De Bruin-Weller M., Barbarot S., et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021; 157(9): 1047–55. https://doi.org/10.1001/jamadermatol.2021.3023Nezamololama N., Fieldhouse K., Metzger K., Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context. 2020; 9: 2020-8-5. https://doi.org/10.7573/dic.2020-8-5Nezamololama N., Fieldhouse K., Metzger K., Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context. 2020; 9: 2020-8-5. https://doi.org/10.7573/dic.2020-8-5Guttman-Yassky E., Thaçi D., Pangan A.L., Hong H.C., Papp K.A., Reich K., et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2020; 145(3): 877-84. https://doi.org/10.1016/j.jaci.2019.11.025Guttman-Yassky E., Thaçi D., Pangan A.L., Hong H.C., Papp K.A., Reich K., et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2020; 145(3): 877–84. https://doi.org/10.1016/j.jaci.2019.11.025Ferreira S., Guttman-Yassky E., Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. Am. J. Clin. Dermatol. 2020; 21(6): 783-98. https://doi.org/10.1007/s40257-020-00548-6Ferreira S., Guttman-Yassky E., Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. Am. J. Clin. Dermatol. 2020; 21(6): 783–98. https://doi.org/10.1007/s40257-020-00548-6Guttman-Yassky E., Teixeira H.D., Simpson E.L., Papp K.A., Pangan A.L., Blauvelt A., et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021; 397(10290): 2151-68. https://doi.org/10.1016/S0140-6736(21)00588-2Guttman-Yassky E., Teixeira H.D., Simpson E.L., Papp K.A., Pangan A.L., Blauvelt A., et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021; 397(10290): 2151–68. https://doi.org/10.1016/S0140-6736(21)00588-2Simpson E.L., Papp K.A., Blauvelt A., Chu C.Y., Hong H.C., Katoh N., et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2022; 158(4): 404-13. https://doi.org/10.1001/jamadermatol.2022.0029Simpson E.L., Papp K.A., Blauvelt A., Chu C.Y., Hong H.C., Katoh N., et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2022; 158(4): 404–13. https://doi.org/10.1001/jamadermatol.2022.0029Nogueira M., Torres T. Janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib. Dermatol. Pract. Concept. 2021; 11(4): e2021145. https://doi.org/10.5826/dpc.1104a145Nogueira M., Torres T. Janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib. Dermatol. Pract. Concept. 2021; 11(4): e2021145. https://doi.org/10.5826/dpc.1104a145Reich K., Teixeira H.D., de Bruin-Weller M., Bieber T., Soong W., Kabashima K., et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10290): 2169-81. https://doi.org/10.1016/S0140-6736(21)00589-4Reich K., Teixeira H.D., de Bruin-Weller M., Bieber T., Soong W., Kabashima K., et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10290): 2169–81. https://doi.org/10.1016/S0140-6736(21)00589-4Silverberg J.I., de Bruin-Weller M., Bieber T., Soong W., Kabashima K., Costanzo A., et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. J. Allergy Clin. Immunol. 2022; 149(3): 977-87.e14. https://doi.org/10.1016/j.jaci.2021.07.036Silverberg J.I., de Bruin-Weller M., Bieber T., Soong W., Kabashima K., Costanzo A., et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. J. Allergy Clin. Immunol. 2022; 149(3): 977–87.e14. https://doi.org/10.1016/j.jaci.2021.07.036Shalabi M.M.K., Garcia B., Coleman K., Siller A.Jr., Miller A.C., Tyring S.K. Janus kinase and tyrosine kinase inhibitors in dermatology: a review of their utilization, safety profile and future applications. Skin Therapy Lett. 2022; 27(1): 4-9.Shalabi M.M.K., Garcia B., Coleman K., Siller A.Jr., Miller A.C., Tyring S.K. Janus kinase and tyrosine kinase inhibitors in dermatology: a review of their utilization, safety profile and future applications. Skin Therapy Lett. 2022; 27(1): 4–9.

The authors declare that there are no conflicts of interest present.